Lentitek

Lentitek is a private, pre-revenue platform technology company addressing a critical bottleneck in the advanced therapy sector: the inefficient production of high-quality lentiviral vectors. The company's core innovation involves a novel promoter system that reduces unwanted vector genome splicing and payload breakthrough expression, leading to improved vector potency and manufacturing yields. By offering a drop-in solution compatible with both transient and stable cell line production, Lentitek aims to lower costs and improve the viability of ATMPs, including CAR-T and in-vivo gene therapies. Its mission is to enhance the scalability and accessibility of these transformative treatments.

Proprietary lentiviral vector manufacturing technology utilizing a novel promoter to reduce vector genome splicing and payload breakthrough expression, thereby increasing vector quality, yield, and potency. Designed for easy integration into existing transient or stable cell line production processes.

Lentitek competes in the viral vector optimization space against other biotech startups, large CDMOs developing proprietary processes, and academic initiatives. Competition is based on the magnitude of yield/potency improvement, ease of integration, scalability, and strength of intellectual property.